APOE and chronic kidney disease: Mitigation of IFN‐I response by C‐176 or RUX treatment also remarkably alleviated VSMC premature senescence and phenotypic switching both in Sham/ApoE−/− and CKD/ApoE−/− mice (Figure 8A).